PMID- 18564358
OWN - NLM
STAT- MEDLINE
DCOM- 20081211
LR  - 20210102
IS  - 1365-2141 (Electronic)
IS  - 0007-1048 (Linking)
VI  - 142
IP  - 6
DP  - 2008 Sep
TI  - Understanding and harnessing the graft-versus-leukaemia effect.
PG  - 877-88
LID - 10.1111/j.1365-2141.2008.07260.x [doi]
AB  - The graft-versus-leukaemia (GVL) effect is a central component of the stem cell 
      allograft's ability to cure haematological malignancies. The GVL effect is 
      mediated by donor-derived natural killer cells and T lymphocytes, which have 
      distinct mechanisms of recognizing and targeting the recipient's malignant cells. 
      After transplantation the cytokine milieu is favourable to the early 
      establishment of a GVL effect, but the need to prevent graft-versus-host disease 
      limits the full potential of this process. Clinical studies have identified some 
      critical components of the transplant preparation, donor selection, stem cell 
      source (peripheral blood versus bone marrow) and post-transplant management that 
      can be manipulated to optimize the GVL effect. However, further developments 
      focusing on the selective depletion of unwanted alloreactivity with preservation 
      of GVL effects, and the use of vaccines or the adoptive transfer of 
      leukaemia-specific lymphocytes, will be required to enhance the GVL effect to 
      reliably eradicate more resistant leukaemias.
FAU - Barrett, A John
AU  - Barrett AJ
AD  - Hematology Branch, National Heart, Lung and Blood Institute, National Institutes 
      of Health, Bethesda, MD 20892-1220, USA. barrettj@nhlbi.nih.gov
LA  - eng
GR  - Intramural NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Intramural
PT  - Review
DEP - 20080628
PL  - England
TA  - Br J Haematol
JT  - British journal of haematology
JID - 0372544
RN  - 0 (Cancer Vaccines)
SB  - IM
MH  - Bone Marrow Transplantation/immunology
MH  - Cancer Vaccines/therapeutic use
MH  - Graft vs Leukemia Effect/*immunology
MH  - Humans
MH  - Killer Cells, Natural/immunology
MH  - Leukemia/immunology/*therapy
MH  - T-Lymphocyte Subsets/immunology
MH  - Transplantation Conditioning/methods
RF  - 99
EDAT- 2008/06/20 09:00
MHDA- 2008/12/17 09:00
CRDT- 2008/06/20 09:00
PHST- 2008/06/20 09:00 [pubmed]
PHST- 2008/12/17 09:00 [medline]
PHST- 2008/06/20 09:00 [entrez]
AID - BJH7260 [pii]
AID - 10.1111/j.1365-2141.2008.07260.x [doi]
PST - ppublish
SO  - Br J Haematol. 2008 Sep;142(6):877-88. doi: 10.1111/j.1365-2141.2008.07260.x. 
      Epub 2008 Jun 28.